Want to see TSE:AIDX full AI Analyst Report?
HEALWELL AI (AIDX) Stock Price & Analysis
AIDX Stock Chart & Stats
- Day’s Range
- CAD 0.65 - CAD 0.67
- 52-Week Range
- CAD 0.58 - CAD 1.51
- Previous Close
- CAD 0.70
- Volume
- 263.16K
- Average Volume (3M)
- 137.97K
- Market Cap
- CAD 221.89M
- Enterprise Value
- CAD 287.49M
- Total Cash (Recent Filing)
- CAD 39.81M
- Total Debt (Recent Filing)
- CAD 84.51M
- Price to Earnings (P/E)
- ―
- Beta
- 0.95
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- -0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The sharp first-half revenue increase demonstrates meaningful scale expansion and broader commercial contribution following the Orion acquisition. If integrated effectively, the larger platform can support cross-selling, recurring enterprise contracts, and a stronger base for sustained growth over the next several quarters.
Improving Operating Performance
The substantial improvement in adjusted EBITDA, alongside positive first-half operating cash flow, indicates better operating leverage and execution than the prior-year period. Continued improvement could reduce reliance on external funding and provide greater flexibility to invest in product development and commercialization.
Platform Scale And Clinical Reach
A broad data footprint and large provider reach can strengthen HEALWELL AI’s clinical analytics capabilities and increase the value of its software to healthcare organizations. Demonstrated identification of high-risk patients also supports product credibility and creates a foundation for recurring enterprise adoption.
Bears Say
Persistent Net Losses
Despite stronger revenue and narrower losses, the company has not yet established durable profitability. Persistent net losses constrain internally generated capital, make execution more sensitive to revenue timing, and leave the business needing further operating improvements before earnings can reliably fund expansion.
Negative Free Cash Flow
Negative operating and free cash flow show that the business is still not self-funding on a trailing basis. Although cash burn improved materially, continued investment requirements and uneven contract timing could preserve financing needs until recurring revenue and margins become more consistent.
Enterprise Execution Delays
The shift toward larger recurring enterprise contracts may improve revenue quality, but lengthy sales cycles create timing risk and postpone the payoff from commercial efforts. Delayed recognition can produce uneven results and makes near-term growth dependent on successful contract conversion and deployment.
HEALWELL AI News
AIDX FAQ
What was HEALWELL AI’s price range in the past 12 months?
What is HEALWELL AI’s market cap?
When is HEALWELL AI’s upcoming earnings report date?
How were HEALWELL AI’s earnings last quarter?
Is HEALWELL AI overvalued?
Does HEALWELL AI pay dividends?
What is HEALWELL AI’s EPS estimate?
How many shares outstanding does HEALWELL AI have?
What happened to HEALWELL AI’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HEALWELL AI?
What is the TipRanks Smart Score and how is it calculated?
HEALWELL AI Stock Smart Score
Company Description
HEALWELL AI
Healwell AI Inc., a Toronto-based healthcare technology firm established in 2012, specializes in leveraging artificial intelligence and data science to advance preventative medical care. The company develops an AI-powered platform designed to assist healthcare providers with crucial decision-making. They maintain a significant strategic partnership with WELL Health Technologies Corp., focusing on accelerating the expansion and innovation of AI-driven healthcare solutions. Prior to its current name, adopted in October 2023, the organization was known as MCI Onehealth Technologies Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- James Samuel Lee
- Employees
- 570
- Website
- www.healwell.ai
- Address
- 4881 Yonge Street, Toronto, ON, M6G 1A1, CA
HEALWELL AI (AIDX) Earnings & Revenues
AIDX Earnings Call
Earnings Call SentimentPositive
Overall the call combined strong year‑to‑date financial and operational progress—notably a 60% increase in first‑half revenue (driven by the Orion acquisition), a ~2,574% improvement in first‑half adjusted EBITDA, positive operating cash flow improvement (~145%), and compelling platform scale and clinical validation—with near‑term execution and timing headwinds. The primary negatives were a flat Q2 revenue, a smaller Q2 adjusted EBITDA versus the prior year quarter, gross‑margin mix pressure, subscription volatility that prompted investor questions, and longer enterprise sales cycles causing revenue recognition timing risks. Management emphasized that the business is transitioning through the trough of integration into an enterprise recurring model and is targeting ~10% adjusted EBITDA margin by year‑end, while expecting some AI/DS growth to be realized later as enterprise contracts are deployed.
View all TSE:AIDX earnings summariesAIDX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |
